Xiamen, China

Dandan Chen

This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Xiamen Sinopeg Biotech, Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dandan Chen. Retrieved from https://idiyas.com/inventor/dandan-chen-dqscqr3d

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dandan Chen - Innovator in Non-Linear PEGylated Lipids.

Introduction

Dandan Chen is an inventor based in Xiamen, China. She is known for her work in the field of non-linear PEGylated lipids. Her innovative approaches aim to enhance drug delivery systems and improve the efficacy of pharmaceutical compositions.

Latest Patent Applications

Dandan Chen has submitted several notable patent applications. One of her latest applications is titled "NON-LINEAR PEGYLATED LIPID AND APPLICATION THEREOF." This invention discloses a non-linear PEGylated lipid that offers better protective effects toward modified lipid nanoparticles (LNPs) compared to linear PEGylated lipids. The lipid pharmaceutical composition demonstrates high efficiency in drug encapsulation, appropriate particle size, non-toxicity, and good stability in serum. Another significant application is "NON-LINEAR PEGYLATED LIPID CONTAINING A TERTIARY AMINE AND APPLICATION THEREOF." This invention includes a non-linear PEGylated lipid that contains a tertiary amine, which enhances surface modification of LNPs, extends systemic circulation, and reduces biological toxicity. The LNP pharmaceutical composition shows excellent drug delivery capabilities and higher pharmaceutical efficacy.

Conclusion

Dandan Chen is making significant contributions to the field of pharmaceutical innovations through her research on non-linear PEGylated lipids. Her work has the potential to improve drug delivery systems and enhance therapeutic outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…